JPWO2021132591A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021132591A5
JPWO2021132591A5 JP2021567687A JP2021567687A JPWO2021132591A5 JP WO2021132591 A5 JPWO2021132591 A5 JP WO2021132591A5 JP 2021567687 A JP2021567687 A JP 2021567687A JP 2021567687 A JP2021567687 A JP 2021567687A JP WO2021132591 A5 JPWO2021132591 A5 JP WO2021132591A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021567687A
Other languages
English (en)
Other versions
JPWO2021132591A1 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/048803 external-priority patent/WO2021132591A1/ja
Publication of JPWO2021132591A1 publication Critical patent/JPWO2021132591A1/ja
Priority to JP2022097020A priority Critical patent/JP7201192B2/ja
Publication of JPWO2021132591A5 publication Critical patent/JPWO2021132591A5/ja
Pending legal-status Critical Current

Links

Claims (1)

  1. 本明細書に記載された発明。
JP2021567687A 2019-12-26 2020-12-25 Pending JPWO2021132591A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022097020A JP7201192B2 (ja) 2019-12-26 2022-06-16 エクソン50のスキッピングを誘導するアンチセンス核酸

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019236704 2019-12-26
PCT/JP2020/048803 WO2021132591A1 (ja) 2019-12-26 2020-12-25 エクソン50のスキッピングを誘導するアンチセンス核酸

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022097020A Division JP7201192B2 (ja) 2019-12-26 2022-06-16 エクソン50のスキッピングを誘導するアンチセンス核酸

Publications (2)

Publication Number Publication Date
JPWO2021132591A1 JPWO2021132591A1 (ja) 2021-07-01
JPWO2021132591A5 true JPWO2021132591A5 (ja) 2024-01-09

Family

ID=76574765

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021567687A Pending JPWO2021132591A1 (ja) 2019-12-26 2020-12-25
JP2022097020A Active JP7201192B2 (ja) 2019-12-26 2022-06-16 エクソン50のスキッピングを誘導するアンチセンス核酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022097020A Active JP7201192B2 (ja) 2019-12-26 2022-06-16 エクソン50のスキッピングを誘導するアンチセンス核酸

Country Status (14)

Country Link
US (2) US20230073008A1 (ja)
EP (1) EP4083208A4 (ja)
JP (2) JPWO2021132591A1 (ja)
KR (1) KR20220122673A (ja)
CN (1) CN114901823A (ja)
AU (1) AU2020411964A1 (ja)
BR (1) BR112022012622A2 (ja)
CA (1) CA3165961A1 (ja)
CO (1) CO2022008664A2 (ja)
IL (1) IL294271A (ja)
MX (1) MX2022007937A (ja)
TW (1) TW202138560A (ja)
WO (1) WO2021132591A1 (ja)
ZA (1) ZA202206667B (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
EP0506830B1 (en) 1989-12-20 2005-12-14 Avi Biopharma, Inc. Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
JP2924179B2 (ja) 1993-02-19 1999-07-26 日本新薬株式会社 グリセロール誘導体,デバイス及び医薬組成物
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
ES2566628T3 (es) 2002-11-25 2016-04-14 Masafumi Matsuo Fármacos de ácido nucleico ENA que modifican el corte y empalme en precursores de ARNm
EP4047096A1 (en) 2004-06-28 2022-08-24 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
LT2024499T (lt) 2006-05-10 2018-02-26 Sarepta Therapeutics, Inc. Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų
ES2694726T3 (es) 2007-06-29 2018-12-26 Sarepta Therapeutics, Inc. Conjugados peptídicos específicos de tejido y métodos
MX2010004955A (es) 2007-11-15 2010-06-30 Avi Biopharma Inc Metodo de sintesis de oligomeros de morfolina.
EP3428278A1 (en) * 2008-10-24 2019-01-16 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for dmd
PT2607484E (pt) 2008-10-27 2016-03-09 Academisch Ziekenhuis Leiden Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
CN101388842B (zh) 2008-10-30 2012-04-04 华为技术有限公司 一种存储方法和装置
CN103003430A (zh) 2009-11-12 2013-03-27 西澳大利亚大学 反义分子和治疗疾病的方法
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
JP6478632B2 (ja) 2011-05-05 2019-03-06 サレプタ セラピューティクス, インコーポレイテッド ペプチドオリゴヌクレオチドコンジュゲート
JP2013100190A (ja) 2011-11-07 2013-05-23 Fumihiro Mitamura コンクリート組成物の製造方法
CN117721110A (zh) 2011-12-28 2024-03-19 日本新药株式会社 反义核酸
NZ631289A (en) * 2013-03-15 2017-08-25 Sarepta Therapeutics Inc Improved compositions for treating muscular dystrophy
KR20240035901A (ko) 2015-05-19 2024-03-18 사렙타 쎄러퓨틱스 인코퍼레이티드 펩티드 올리고뉴클레오티드 콘주게이트
SI3331891T1 (sl) 2015-08-05 2022-04-29 Eisai R&D Management Co., Ltd. Postopek priprave v bistvu diastereomerno čistega fosforodiamidatnega oligomera, fosforodiamidatni oligomer izdelan po takem postopku in farmacevtski sestavek, ki vsebuje tak fosforodiamidatni oligomer
EP3359523A4 (en) 2015-10-09 2019-07-24 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
EP3359668A4 (en) * 2015-10-09 2019-06-05 Sarepta Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATING DUCHENNE MUSCLE DYSTROPHY AND ASSOCIATED ILLNESSES THEREOF
WO2018014042A1 (en) * 2016-07-15 2018-01-18 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of dystrophin transcript
WO2018118599A1 (en) 2016-12-19 2018-06-28 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
CA3047010A1 (en) 2016-12-19 2018-06-28 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
LT3554554T (lt) 2016-12-19 2022-11-25 Sarepta Therapeutics, Inc. Egzoną praleidžiantys oligomero konjugatai nuo raumenų distrofijos
BR112021011018A2 (pt) 2018-12-13 2021-08-31 Sarepta Therapeutics, Inc. Conjugados de oligômero para exon skipping para distrofia muscular

Similar Documents

Publication Publication Date Title
JP2021151238A5 (ja)
JP2024036694A5 (ja)
JP2021048879A5 (ja)
JP2021184963A5 (ja)
JP2023105131A5 (ja)
JP2020040981A5 (ja)
JP2020007340A5 (ja)
JP2022184985A5 (ja)
JP2021028398A5 (ja)
JPWO2020148954A5 (ja)
JP2022185040A5 (ja)
JP2022122972A5 (ja)
JP2022116141A5 (ja)
JP2021100406A5 (ja)
JP2024012435A5 (ja)
JP2023181322A5 (ja)
JP2023166402A5 (ja)
JP2020079331A5 (ja)
JP2023052878A5 (ja)
JP2023085489A5 (ja)
JP2022064180A5 (ja)
JP2022060220A5 (ja)
JP2019081810A5 (ja)
JP2023145479A5 (ja)
JP2023041070A5 (ja)